CVA-Direct Oral Anticoagulants (DOACs): Bleeding Management and Reversal Strategies

June 10, 2020

Historically, warfarin has been commonly used for both the management of prophylaxis and treatment in venous thromboembolism (VTE) and nonvalvular atrial fibrillation (NVAF) stroke prophylaxis. The risks associated with warfarin are well-established and the role of various agents for reversal is well understood. However, newer agents, referred to as direct oral anticoagulants (DOACs), have been approved for these same indications. Based on the current robust medical evidence, recent guideline updates have placed a preference on the use of DOACs over warfarin for most patient populations in need of oral anticoagulation. However, methods to manage bleeding associated with each DOACs , and the efficacy and safety of new reversal agents is not well understood.

The desired outcome of this presentation is to ensure our clinicians have the necessary information and resources needed to appropriately treat bleeding in patients using a DOAC for anticoagulation. Attendees will have an increased understanding of each reversal agent for each DOAC, including safety and efficacy, and awareness of its appropriate place in therapy. This presentation will facilitate the continued improvement of safety and quality care in the patient population requiring oral anticoagulants. 

Target Audience

Adult and Family Medicine, Gerontology, Nephrology, Cardiology, Hematology/Oncology, Hospital-Based Specialists, Emergency Medicine, and Pharmacy will be leading this initiative.

Learning Objectives

  • Understand the strategies and complications for each reversal agent
  • Recommend the appropriate reversal agent based on clinical factors and understand monitoring parameters
Course summary
Course opens: 
Course expires: 
Event starts: 
06/10/2020 - 12:30pm PDT
Event ends: 
06/10/2020 - 1:30pm PDT

Kaiser Permanente Central Valley is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians. The Kaiser Permanente Central Valley designates this Live Activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure: The presenter & planning committee members for this activity have disclosed that they have no relevant relationships with commercial or industry organizations. The CME Department has reviewed their disclosure information for the planner(s) and/or committee/faculty for this program and they do not have relationships that present a relevant conflict of interest. Kaiser Permanente does not endorse any brand name products.

Please login or register to take this course.